(Q34628386)

English

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

ChEBI release 2020-05-28

Parkinson's disease

1 reference

based on heuristic

inferred from title

Fabrizio Stocchi

object named as

Fabrizio Stocchi

9

0 references

object named as

Anthony Lang

5

0 references

8

object named as

Werner Poewe

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

10

object named as

Eduardo Tolosa

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1

object named as

Olivier Rascol

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Joseph Jankovic

4

object named as

Joseph Jankovic

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Robert A Hauser

3

object named as

Robert Hauser

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Charles Warren Olanow

13

object named as

C Warren Olanow

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

William John Langston

6

object named as

J William Langston

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

7

object named as

Eldad Melamed

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Cheryl J Fitzer-Attas

2

object named as

Cheryl J Fitzer-Attas

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Eli Eyal

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Yoni M Weiss

12

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

7 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

415-423

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

The scientific and clinical basis for the treatment of Parkinson disease (2009).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The therapeutic potential of monoamine oxidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Discordant effects of rasagiline doses in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Does rasagiline have a disease-modifying effect on Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Slowing the decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative responsiveness of Parkinson's disease scales to change over time.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

UPDRS activity of daily living score as a marker of Parkinson's disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The Parkinson fatigue scale.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Levodopa and the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Can focusing on UPDRS Part II make assessments of Parkinson disease progression more efficient?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of fatigue on quality of life in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ageing and Parkinson's disease: substantia nigra regional selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms compensating for dopamine loss in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Disease progression, drug action and Parkinson's disease: why time cannot be ignored

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical features at first visit and rapid disease progression in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining the Parkinson's disease phenotype: initial symptoms and baseline characteristics in a clinical cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical heterogeneity in newly diagnosed Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression of motor impairment and disability in Parkinson disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Gender differences in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Tremor at onset. Predictor of cognitive and motor outcome in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of onset age on the clinical features of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Functional decline in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970073-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(11)70073-4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34628386&oldid=1756307014"